Trials / Withdrawn
WithdrawnNCT05691400
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to estimate the effect of CYP3A4\*22 on the clearance and area under the plasma concentration-time curve of Palbociclib, Ribociclib, and Abemaciclib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib 125Mg Tab | 125 mg single dose |
| DRUG | Ribociclib 200Mg Oral Tablet | 200 mg single dose |
| DRUG | Abemaciclib 150 MG Oral Tablet | 150 mg single dose |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2023-01-20
- Last updated
- 2024-02-02
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05691400. Inclusion in this directory is not an endorsement.